Get 20% Off All Market Studies With Code ONLINE20 – Anticipate Tariff Impacts, Market Disruptors, and Long-Term Growth Trends
What Are the Key Factors Driving Oral Hypoglycemic Agents Market Size and Growth?
The oral hypoglycemic agents market size has grown steadily in recent years. It will grow from $57.04 billion in 2024 to $59.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to the growing prevalence of type 2 diabetes, rising geriatric population, growing awareness of diabetes management, expansion of healthcare access in emerging markets, and the preference for oral over injectable therapies.
The oral hypoglycemic agents market size is expected to see steady growth in the next few years. It will grow to $72.09 billion in 2029 at a compound annual growth rate (CAGR) of 4.9%. The growth in the forecast period can be attributed to rising demand for combination therapies, supportive government healthcare policies, increasing adoption of telemedicine for diabetes care, rising investment in research and development for diabetes treatments, and rising focus on personalized diabetes treatment. Major trends in the forecast period include the development of novel oral antidiabetics, the development of fixed-dose combinations, technological advancements in drug formulation, a focus on reducing drug side effects, and the integration of digital health tools for glucose monitoring.
Claim your free report sample now:
What Are the Key Factors Contributing to Oral Hypoglycemic Agents Market Growth?
The rise in type 2 diabetes prevalence is expected to propel the growth of the oral hypoglycemic agents market going forward. Type 2 diabetes refers to a chronic metabolic disorder characterized by the body’s ineffective use of insulin, leading to elevated blood glucose levels. Type 2 diabetes is rising due to the increasing prevalence of sedentary lifestyles, which significantly reduce physical activity and contribute to obesity and insulin resistance. Oral hypoglycemic agents help manage type 2 diabetes by lowering blood glucose levels through various mechanisms, such as enhancing insulin sensitivity, stimulating insulin secretion, or reducing glucose absorption. For instance, in April 2025, according to the International Diabetes Federation (IDF), a Belgium-based non-profit organization, nearly 589 million adults aged 20–79 are living with diabetes worldwide, and this number is projected to rise significantly to 853 million by 2050. Therefore, the rising incidence of type 2 diabetes drives growth in the oral hypoglycemic agents market.
Which Segment Holds the Largest Share in the Oral Hypoglycemic Agents Market?
The oral hypoglycemic agents market covered in this report is segmented –
1) By Product Type: Sulfonylureas, Metformin, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Immunotherapy
2) By Administration Route: Oral Tablets, Oral Liquids, Extended-Release Formulations, Combination Therapy Formulations
3) By Patient Type: Type 2 Diabetes Mellitus Patients, Pre-diabetic Patients, Obese Or Overweight Patients, Patients with Multiple Comorbidities
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Nursing Homes and Long-Term Care Facilities
5) By End users: Hospitals, Clinics
Subsegments:
1) By Sulfonylureas: Glipizide, Glyburide, Glimepiride, Chlorpropamide, Tolbutamide
2) By Metformin: Immediate-Release Metformin, Extended-Release Metformin (XR), Combination Metformin
3) By Thiazolidinediones (TZDs): Pioglitazone, Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose, Miglitol, Voglibose
5) By Immunotherapy: Teplizumab, Alum-Formulated GAD (GAD-Alum), Diamyd, Anti-CD3 Monoclonal Antibodies
What Are the Key Trends Shaping the Oral Hypoglycemic Agents Market?
Major companies operating in the oral hypoglycemic agents market are focusing on developing advanced therapeutic solutions, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, to improve blood sugar control in patients with Type 2 diabetes. Dipeptidyl peptidase-4 (DPP-4) inhibitors are type 2 diabetes medications that boost incretin hormone levels, enabling the body to produce insulin, thereby lowering blood sugar levels. For instance, in June 2022, Gan & Lee Pharmaceuticals Co. Ltd., a China-based pharmaceutical company, received approval for Sitagliptin Phosphate tablets, a self-developed oral hypoglycemic medication designed to manage Type 2 diabetes effectively. This product offers an effective treatment option by inhibiting the DPP-4 enzyme, which helps regulate blood sugar levels. This launch marks Ganlee Pharmaceuticals' entry into the generic drug market, offering a cost-effective alternative for managing type 2 diabetes.
Who Are the Emerging Players in the Oral Hypoglycemic Agents Market?
Major companies operating in the oral hypoglycemic agents market are Pfizer Inc., Janssen Global Services LLC, Merck Sharp & Dohme Corp., Bayer AG, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceuticals Limited, Eli Lilly and Company, Boehringer Ingelheim Ltd., Novo Nordisk A/S, Astellas Pharma Inc., Laboratoires Servier, Huadong Medicine Co. Ltd., Tonghua Dongbao Pharmaceutical Co. Ltd., Gan & Lee Pharmaceuticals Co. Ltd., Biocon Limited, Wanbang Biopharmaceuticals Co. Ltd.
Get the full oral hypoglycemic agents market report here:
What Are the Regional Opportunities for Investment in the Oral Hypoglycemic Agents Market?
North America was the largest region in the oral hypoglycemic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral hypoglycemic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: The Business Research Company | LinkedIn
Comments
Post a Comment